Morningstar

uniQure NV QURE

Morningstar Rating

UniQure's Fabry Disease Treatment Gets Orphan Drug Designation from FDA

Global News Select Sep 23, 2024 11:51am
uniQure Announces Orphan Drug Designation Granted to AMT-191 for the Treatment of Fabry Disease

GlobeNewswire Sep 23, 2024 11:05am
uniQure Announces Dosing of First Patient in Phase I/IIa Clinical Trial of AMT-191 for the Treatment of Fabry Disease

GlobeNewswire Aug 15, 2024 11:05am
uniQure Announces Second Quarter 2024 Financial Results and Provides Company Update

GlobeNewswire Aug 1, 2024 11:05am
uniQure Announces Closing of Sale of Manufacturing Facility to Genezen

GlobeNewswire Jul 23, 2024 11:05am
uniQure Announces Positive Interim Data Update Demonstrating Slowing of Disease Progression in Phase I/II Trials of AMT-130 for Huntington’s Disease

GlobeNewswire Jul 9, 2024 11:05am
Genezen to Acquire uniQure's Commercial Gene Therapy Manufacturing Operations in Lexington, MA

PR Newswire Jul 1, 2024 11:05am
uniQure Announces Sale of Commercial Manufacturing Facility to Genezen

GlobeNewswire Jul 1, 2024 11:05am
UniQure's AMT-130 Gets FDA RMAT Designation in Huntington's Disease

Global News Select Jun 3, 2024 11:54am
UniQure to cut 28% of workforce and scrap more than half its research projects in strategic overhaul

MarketWatch Oct 5, 2023 12:19pm
Re/Max, UniQure and Trinseo Fall to 52-Week Lows on Exit From S&P SmallCap 600

Global News Select Sep 5, 2023 5:44pm

Sponsor Center

Transparency is our policy. Learn how it impacts everything we do

Transparency is how we protect the integrity of our work and keep empowering investors to achieve their goals and dreams. And we have unwavering standards for how we keep that integrity intact, from our research and data to our policies on content and your personal data.

We’d like to share more about how we work and what drives our day-to-day business.

How we make money

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions. Our investment management business generates asset-based fees, which are calculated as a percentage of assets under management. We also sell both admissions and sponsorship packages for our investment conferences and advertising on our websites and newsletters.

How we use your personal data

How we use your information depends on the product and service that you use and your relationship with us. We may use it to:

Verify your identity, personalize the content you receive, or create and administer your account.
Provide specific products and services to you, such as portfolio management or data aggregation.
Develop and improve features of our offerings.
Gear advertisements and other marketing efforts towards your interests.

To learn more about how we handle and protect your data, visit our privacy center.

How we approach editorial content

Maintaining independence and editorial freedom is essential to our mission of empowering investor success. We provide a platform for our authors to report on investments fairly, accurately, and from the investor’s point of view. We also respect individual opinions––they represent the unvarnished thinking of our people and exacting analysis of our research processes. Our authors can publish views that we may or may not agree with, but they show their work, distinguish facts from opinions, and make sure their analysis is clear and in no way misleading or deceptive.

To further protect the integrity of our editorial content, we keep a strict separation between our sales teams and authors to remove any pressure or influence on our analyses and research.

Read our editorial policy to learn more about our process.

© Copyright 2024 Morningstar, Inc. All rights reserved. Dow Jones Industrial Average, S&P 500, Nasdaq, and Morningstar Index (Market Barometer) quotes are real-time.